Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Larotinib · Z650

Small molecule · Inhibitor of ErbB receptor tyrosine kinases (EGFR family) · developed by Sunshine Lake Pharma Co.

Phase 3 Most advanced trial
SBFM Developer
2 Registered trials

What is Larotinib?

Larotinib is an oral reversible pan-ErbB tyrosine kinase inhibitor that binds and inhibits ErbB receptors, the EGFR family. It is studied in esophageal cancer and advanced solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Z650, Lerotinib
Drug type
Small molecule
Targets
ErbB receptor tyrosine kinases (EGFR family)
Mechanism
Inhibitor of ErbB receptor tyrosine kinases (EGFR family)
Pathways
angiogenesis, tumor cell proliferation
Therapy area
Oncology
Developer
Sunshine Lake Pharma Co., Ltd. (SBFM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04415853 Phase 3 Esophageal Cancer Recruiting SBFM
NCT05048368 Phase 1 Esophageal Cancer Withdrawn SBFM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Esophageal CancerAdvanced Solid Tumor

More from Sunshine Lake Pharma Co.

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.

Follow SBFM, the company behind Larotinib

See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SBFM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.